212 related articles for article (PubMed ID: 33652777)
1. Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral Drugs.
Ridziauskas M; Zablockienė B; Jančorienė L; Samuilis A; Zablockis R; Jackevičiūtė A
Medicina (Kaunas); 2021 Feb; 57(3):. PubMed ID: 33652777
[No Abstract] [Full Text] [Related]
2. Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment.
Stasi C; Sadalla S; Carradori E; Monti M; Petraccia L; Madia F; Gragnani L; Zignego AL
Curr Med Res Opin; 2020 Feb; 36(2):245-249. PubMed ID: 31702411
[No Abstract] [Full Text] [Related]
3. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
4. Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients.
Yoo SH; Kwon JH; Nam SW; Kim HY; Kim CW; You CR; Choi SW; Cho SH; Han JY; Song DS; Chang UI; Yang JM; Lee HL; Lee SW; Han NI; Kim SH; Song MJ; Hwang S; Sung PS; Jang JW; Bae SH; Choi JY; Yoon SK
J Viral Hepat; 2018 Oct; 25(10):1189-1196. PubMed ID: 29660199
[TBL] [Abstract][Full Text] [Related]
5. Liver stiffness improvement in hepatitis C patients after successful treatment.
Brakenhoff SM; Verburgh ML; Willemse SB; Baak LC; Brinkman K; van der Valk M
Neth J Med; 2020 Dec; 78(6):368-375. PubMed ID: 33380534
[TBL] [Abstract][Full Text] [Related]
6. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.
Wang JH; Yen YH; Yao CC; Hung CH; Chen CH; Hu TH; Lee CM; Lu SN
Liver Int; 2016 Dec; 36(12):1793-1799. PubMed ID: 27254286
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
[TBL] [Abstract][Full Text] [Related]
8. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients.
Owusu Sekyere S; Port K; Deterding K; Cornberg M; Wedemeyer H
United European Gastroenterol J; 2021 May; 9(4):486-496. PubMed ID: 33349201
[TBL] [Abstract][Full Text] [Related]
10. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
[TBL] [Abstract][Full Text] [Related]
11. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals.
Tamaki N; Higuchi M; Kurosaki M; Kirino S; Osawa L; Watakabe K; Wang W; Okada M; Shimizu T; Takaura K; Takada H; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Enomoto N; Izumi N
J Viral Hepat; 2019 Jul; 26(7):893-899. PubMed ID: 30974045
[TBL] [Abstract][Full Text] [Related]
12. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis.
Masetti C; Lionetti R; Lupo M; Siciliano M; Giannelli V; Ponziani FR; Teti E; Dell'Unto C; Francioso S; Brega A; Montalbano M; Visco-Comandini U; Taibi C; Galati G; Vespasiani Gentilucci U; Picardi A; Andreoni M; Pompili M; Pellicelli AM; D'Offizi G; Gasbarrini A; De Santis A; Angelico M
J Viral Hepat; 2018 Dec; 25(12):1493-1500. PubMed ID: 30112854
[TBL] [Abstract][Full Text] [Related]
13. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
14. Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens.
Attia D; Deterding K; Cornberg J; Gebel MJ; Cornberg M; Manns MP; Wedemeyer H; Potthoff A
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):67-74. PubMed ID: 30239347
[TBL] [Abstract][Full Text] [Related]
15. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.
Alonso López S; Manzano ML; Gea F; Gutiérrez ML; Ahumada AM; Devesa MJ; Olveira A; Polo BA; Márquez L; Fernández I; Cobo JCR; Rayón L; Riado D; Izquierdo S; Usón C; Real Y; Rincón D; Fernández-Rodríguez CM; Bañares R
Hepatology; 2020 Dec; 72(6):1924-1934. PubMed ID: 33022803
[TBL] [Abstract][Full Text] [Related]
16. Reply to: "Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma".
Genescà J
J Hepatol; 2020 Nov; 73(5):1289-1290. PubMed ID: 32854982
[No Abstract] [Full Text] [Related]
17. Glycomics-based serum markers as reliable tool for assessment of viral response after treatment with direct-acting antiviral drugs in hepatitis C virus infection.
Somers N; Vandekerckhove E; Geerts A; Degroote H; Lefere S; Devisscher L; Meuris L; Callewaert N; Van Vlierberghe H; Verhelst X
Acta Clin Belg; 2023 Apr; 78(2):96-102. PubMed ID: 35505274
[TBL] [Abstract][Full Text] [Related]
18. Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment.
Lin MT; Chang KC; Yen YH; Tsai MC; Chen CH; Wang JH; Hsiao CC; Chiu YH; Hu TH
J Formos Med Assoc; 2021 Jan; 120(1 Pt 3):621-628. PubMed ID: 32718890
[TBL] [Abstract][Full Text] [Related]
19. Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience.
Rinaldi L; Guarino M; Perrella A; Pafundi PC; Valente G; Fontanella L; Nevola R; Guerrera B; Iuliano N; Imparato M; Trabucco A; Sasso FC; Morisco F; Ascione A; Piai G; Adinolfi LE
Dig Dis Sci; 2019 Oct; 64(10):3013-3019. PubMed ID: 30937719
[TBL] [Abstract][Full Text] [Related]
20. The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?
Blanco JR; Rivero-Juárez A
Expert Rev Anti Infect Ther; 2016 Nov; 14(11):993-996. PubMed ID: 27686837
[No Abstract] [Full Text] [Related]
[Next] [New Search]
